Bonaventura Clotet

发表

Bayesian network analysis of mutational pathways to DRV resistance

Kristof Theys, Kristel Van Laethem, Maurizio Zazzi, 2012 .

SARS-CoV-2 transmission in an indoor mass-gathering live music event. A randomized clinical trial.

Lidia Ruiz, Jordi Puig, Bonaventura Clotet, 2021 .

Update of the drug resistance mutations in HIV-1: Fall 2006.

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus

Christos J. Petropoulos, Terri Wrin, Lidia Ruiz, 2006, The Journal of experimental medicine.

Drug uptake transporters in antiretroviral therapy.

Bonaventura Clotet, B. Clotet, J. Martinez-Picado, 2011, Pharmacology & therapeutics.

Discovery of Novel Non‐Cyclam Polynitrogenated CXCR4 Coreceptor Inhibitors

Violeta I. Pérez-Nueno, Jordi Teixidó, Sofia Pettersson, 2008, ChemMedChem.

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

Bonaventura Clotet, A. LaMarca, B. Clotet, 2012, The Lancet. Infectious diseases.

Update of the drug resistance mutations in HIV-1: Spring 2008.

Huldrych F Günthard, Deenan Pillay, Victoria A Johnson, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

, Eva Mediator Complex in HIV-1 Transcription Characterization of the Influence of Microbiology

Eduardo Pauls, José A. Esté, Bonaventura Clotet, 2014 .

Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts

Lidia Ruiz, Bonaventura Clotet, Eugènia Negredo, 2002, HIV clinical trials.

Felipe García Control of HIV-1 Replication Based Vaccine Elicits T Cell Responses Associated with − A Dendritic Cell

Felipe García, Brigitte Autran, Agathe León, 2012 .

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Lidia Ruiz, Bonaventura Clotet, B. Clotet, 2002, AIDS.

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

Lidia Ruiz, Cristian Tebé, Jordi Puig, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Update of the Drug Resistance Mutations in HIV-1: December 2008

Deenan Pillay, Victoria A Johnson, Francoise Brun-Vezinet, 2008 .

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Victoria A Johnson, Daniel R Kuritzkes, Françoise Brun-Vézinet, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug resistance mutations in HIV-1.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation

Bikram Chakraborty, Bonaventura Clotet, E. Domingo, 2002, Journal of Virology.

2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.

Ira Musmuca, Rino Ragno, Flavio Ballante, 2012, Journal of medicinal chemistry.

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Klaus Korn, Kristof Theys, Anne-Mieke Vandamme, 2013, Retrovirology.

Update of the drug resistance mutations in HIV-1: Fall 2005.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Christine Katlama, Joep Lange, Adriano Lazzarin, 2003, The New England journal of medicine.

Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif

Jordi Villà-Freixa, Jorge Carrillo, Cristina Vilaplana, 2017, Scientific Reports.

Alternation of Antiretroviral Drug Regimens for HIV Infection

Lidia Ruiz, Kurt Hertogs, Ayumi Shintani, 2003, Annals of Internal Medicine.

Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1

Christos J. Petropoulos, Terri Wrin, Simon D. W. Frost, 2005, Journal of Virology.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Roger Paredes, Esteban Martinez, Bonaventura Clotet, 2018, The Journal of antimicrobial chemotherapy.

Novel Monocyclam Derivatives as HIV Entry Inhibitors: Design, Synthesis, Anti‐HIV Evaluation, and Their Interaction with the CXCR4 Co‐receptor

Jordi Teixidó, Sofia Pettersson, Violeta I Pérez-Nueno, 2010, ChemMedChem.

Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients

Lidia Ruiz, Roger Paredes, Bonaventura Clotet, 2007, AIDS.

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Rolf Kaiser, Anne-Mieke Vandamme, Stijn Imbrechts, 2013, PloS one.

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.

David Dunn, Kholoud Porter, Rodolphe Thiébaut, 2011, The Lancet. Infectious diseases.

Update of the drug resistance mutations in HIV-1: 2004.

Amalio Telenti, Deenan Pillay, Victoria A Johnson, 2004, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Antiretroviral Agents Effectively Block HIV Replication after Cell-to-Cell Transfer

José A. Esté, Bonaventura Clotet, B. Clotet, 2012, Journal of Virology.

Epistasis among deleterious mutations in the HIV-1 protease.

Bonaventura Clotet, B. Clotet, M. Parera, 2009, Journal of molecular biology.

Clinically Validated Genotype Analysis: Guiding Principles and Statistical Concerns

Victor DeGruttola, Vincent Calvez, Maurizio Zazzi, 2004, Antiviral therapy.

Modelled in vivo HIV Fitness under drug Selective Pressure and Estimated Genetic Barrier Towards Resistance are Predictive for Virological Response

Yves Moreau, Kristof Theys, Anne-Mieke Vandamme, 2008, Antiviral therapy.

Anti-HIV Activity and Resistance Profile of the CXC Chemokine Receptor 4 Antagonist POL3026

Eduardo Pauls, Mercedes Armand-Ugón, Imma Clotet-Codina, 2008, Molecular Pharmacology.

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Pietro Vernazza, Simon Collins, Gilles Wandeler, 2016, JAMA.

HIV-1 Protease Catalytic Efficiency Effects Caused by Random Single Amino Acid Substitutions

Bonaventura Clotet, B. Clotet, M. Parera, 2006, Molecular biology and evolution.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Anders Karlsson, Edwin DeJesus, Bonaventura Clotet, 2008, The New England journal of medicine.

Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.

Jordi Teixidó, Bonaventura Clotet, José I Borrell, 2012, Journal of medicinal chemistry.

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Sarah Palmer, Roger Paredes, Viktor Dahl, 2010, Nature Medicine.